Skip to content
Home/Companies/Biotech/Fusion Antibodies

Fusion Antibodies

Biotech·UK·Exited 2017·Held 4yr
Entry
2013
Hold
4yr
Exit
2017

Who owns Fusion Antibodies?

Fusion Antibodies was owned by Clarendon Fund Managers through Co-Fund NI (2012 vintage) from 2013 to 2017, exited via IPO.

Hand-verified · updated 2026-07-08

Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2017

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
BiotechUK· 2023
Kinsetsu
Active
SaaSUK· 2023
Amply
Amply
Active
BiotechUK· 2022
Angoka
Angoka
Active
CybersecurityUK· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUK· 2022
CV6 Therapeutics
CV6 Therapeutics
Active
BiotechUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Fusion Antibodies

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Fusion Antibodies?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Fusion Antibodies.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue